Pharmacological actions of tetrandrine in inflammatory pulmonary diseases

Acta Pharmacologica Sinica

Volumn 23, Issue 12, 2002, Pages 1107-1113

  Xie, Qiang Min ^a   Tang, Hui Fang ^a   Chen, Ji Qiang ^a   Bian, Ru Lian ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Asthma; Pulmonary hypertension; Silicosis; Tetrandrine

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BISBENZYLISOQUINOLINE ALKALOID; BLEOMYCIN; BLEOMYCIN A5; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CHINESE DRUG; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CROTON OIL; FORMALDEHYDE; GUAIFENESIN; HERBACEOUS AGENT; HISTAMINE; HYDROCORTISONE; IMMUNOGLOBULIN E; ISOPRENALINE; LEUKOTRIENE D4; MONOCROTALINE; NEDOCROMIL; POLYVINYLPYRIDINE 1 OXIDE; QUINOLYLPIPERAZINE HYDROXYLPHOSPHATE TETRANDRINE; TETRANDRINE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ALLERGY; ANIMAL CELL; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRITIS; ASTHMA; CHINESE MEDICINE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SAFETY; EDEMA; FORCED EXPIRATORY VOLUME; HERBAL MEDICINE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG DISEASE; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PULMONARY HYPERTENSION; RAT; SIDE EFFECT; SILICOSIS; THROMBOCYTE AGGREGATION INHIBITION; TRADITIONAL MEDICINE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ALKALOIDS; ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ASTHMA; BENZYLISOQUINOLINES; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; PLATELET AGGREGATION; SILICOSIS;

EID: 0036905824     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Bian RL, Zhou HL, Xie QM, Tang FD, Yang W, Wang Y. Antiallergic actions of tetrandrine. Chin Tradit Herb Drugs 1984; 15: 262-4.
2. Li W, Zhou HL, Yang QH, Bian RL. Inhibition of the function of rat peritoneal mast cells by tetrandrine. Acta Pharmacol Sin 1987; 8: 450-3.
3. 45Ca influx in tracheal smooth muscles. Acta Pharm Sin 1987; 22: 405-8.
4. Hong JL, Zhou HL, Bian RL. Effects of tetrandrine on cytoplasmic free calcium in rat neutrophils. Acta Pharmacol Sin 1989; 10: 533-7.
5. Xie QM. Stephania tetrandra S. Moore and tetrandrine. In: Bian RL, editors. Antiinflammatory and Immunological Pharmacology & Clinical Application; 1 st Ed. Beijing: Beijing Medical University Publishing House; 1992. p 315-6.
6. Hu S, Merayo-Lloves J, Zhao T, Foster CS. Comparative effectiveness and molecular pharmacological mechanisms of antiallergic agents on experimental conjunctivitis in mice. J Ocul Pharmacol Ther 1998; 14: 67-74.
7. Zhou HL, Bian RL. Studies of Arthus reaction in rabbits and rats. J Zhejiang Med Univ 1988; 17: 112-4.
8. Teh BS, Seow WK, Chalmers AH, Playford S, Ioannoni B, Thong YH. Inhibition of histamine release from rat mast cells by the plant alkaloid tetrandrine. Int Arch Allergy Appl Immunol 1988; 8: 220-4.
9. Zhang HQ, Bian RL. The anti-SRS-A effect of tetrandrine. Acta Pharm Sin 1984; 19: 616-8
10. 4 on trachea and lung strips in gunea pigs. Chin Pharmacol Bull 1988; 4: 307-9.
11. Yang XH, Zhang Y, Guo X. The inhibitory effect of tetrandrine and verapamil on constriction of trachea strip induced by four agonists in guniea pig. J Pract Training Med 1995; 23: 156-8.
12. Wang HL, Liu KJ. The inhibitive effects of tetrandrine on the bioactivity of slow reaction substance-A in broncheal alveolar lavage fluid from hypoxic ventilated rats. J Chin Med Univ 1994; 23: 194-6.
13. Wong CW, Thong YH, Seow WK. Comparative effects of tetrandrine and berbamine on guineapig airway microvascular leakage induced by platelet-activating factor and other allergic mediators. Int J Immunopharmacol 1993; 15: 185-93.
14. Ju XY, Lu ZY, Zhang WP, Wei EQ. Effect of drugs on airway responsiveness in conscious and unbridled guniea pig. Chin J Modem Appl Pharm 1996; 13: 9-11.
15. Chen YY, Kwan CY, Hui SC. Tetrandrine differentially inhibits aggregation and ATP-release of rat platelets. Acta Pharmacol Sin 1996; 17: 105-8.
16. Zhang M, Zhang LZ, Lu JS. Effects of tetrandrine on rabbit platelet aggregation and platelet activating factor generation. Acta Pharmacol Sin 1995; 16: 209-12.
17. 2 generation and calmodulin activity. Acta Pharmacol Sin 1989; 10: 61-5.
18. 2 formation. J Ethnopharmacol 1999; 66: 241-6
19. Xie QM, Zheng QJ, Bian RL. Inhibition of platelet aggregation by tetrandrine. J Zhejiang Med Univ 1989; 18: 7-10.
20. 2 in rabbit blood. Acta Pharmacol Sin 1993; 14: 325-8.
21. Wu S, Zhao Z, Qi H. Effects of tetrandrine on platelet aggregation, platelet adhesion and coagulation. Chin J Chin Materia Med 1990; 15: 233-5, 255-6.
22. Kim HS, Zhang YH, Yun YP. Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation. Planta Med 1999; 65: 135-8.
23. Choi HS, Kim HS, Min KR, Kim Y, Lim HK, Chang YK, et al. Anti-inflammatory effects of fangchinoline and tetrandrine. J Ethnopharmacol 2000; 69: 173-9.
24. Whitehouse MW, Fairlie DP, Thong YH. Anti-inflammatory activity of the isoquinoline alkaloid, tetrandrine, against established adjuvant arthritis in rats. Agents Actions 1994; 42: 123-7.
25. 2. Acta Pharmacol Sin 1994; 15: 477-80.
26. Zhang M, Huang YH, Li A, Yang ZC. Effects of tetrandrine on functions and ultrastructure of alveolar macrophages in smoke inhalation-injured rabbits. Acta Pharmacol Sin 1993; 14: 529-32.
27. He FC, Tang RY, Yao DF. Effects of tetrandrine on vascular permeability and neutrophil function in acute inflammation. Acta Pharmacol Sin 1989; 10: 249-51.
28. Wong CW, Seow WK, O'Callaghan JW, Thong YH. Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. Agents Actions 1992; 36: 112-8.
29. Seow WK, Ferrante A, Li SY, Thong YH. Suppression of human monocyte interleukin 1 production by the plant alkaloid tetrandrine. Clin Exp Immunol 1989; 75: 47-51.
30. Chang DM, Chang WY, Kuo SY, Chang ML. The effects of traditional antirheumatic herbal medicines on immune response cells. J Rheumatol 1997; 24: 436-41.
31. Kang JH, Lewis DM, Castranova V, Rojanasakul Y, Banks DE, Ma JY, et al. Inhibitory action of Tet on macrophage production of interleukin-1 (IL-1)-like activity and thymocyte proliferation. Exp Lung Res 1992; 18: 715-29.
32. Chen F, Sun S, Kuhn DC, Lu Y, Gaydos LJ, Shi X, et al. Tetrandrine inhibits signal-induced NF-kappa B activation in rat alveolar macrophages. Biochem Biophys Res Commun 1997; 231: 99-102.
33. Seow WK, Li SY, Thong YH. Inhibitory effects of tetrandrine on human neutrophil and monocyte adherence. Immunol Lett 1986; 13: 83-8.
34. Shen YC, Chen CF, Wang SY, Sung YJ. Impediment to calcium influx and reactive oxygen production accounts for the inhibition of neutrophil Mac-1 up-regulation and adhesion by tetrandrine. Mol Pharmacol 1999; 55: 186-93.
35. Chang DM, Kuo SY, Lai JH, Chang ML. Effects of antirheumatic herbal medicines on cellular adhesion molecules. Ann Rheum Dis 1999; 58: 366-71.
36. Seow WK, Ferrante A, Goh DB, Chalmers AH, Li SY, Thong YH. In vitro immunosuppressive properties of the plant alkaloid tetrandrine. Int Arch Allergy Appl Immunol 1988; 85: 410-5.
37. Lai JH, Ho LJ, Kwan CY, Chang DM, Lee TC. Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: Potential immunosuppressants in transplantation immunology. Transplantation 1999; 68: 1383-92.
38. Ho LJ, Chang DM, Lee TC, Chang ML, Lai JH. Plant alkaloid Tet downregulates protein kinase C-dependent signaling pathway in T cells. Eur J Pharmacol 1999; 367: 389-98.
39. Tsai JJ, Ma JK, Wang TF, Wang SR, Kao DH. The modulatory effect of tetrandrine on the CD23, CD25 and HLA-DR expression and cytokine production in different groups of asthmatic patients. Int Arch Allergy Immunol 1995; 108: 183-8.
40. Shi X, Mao Y, Saffiotti U, Wang L, Rojanasakul Y, Leonard SS, et al. Antioxidant activity of tetrandrine and its inhibition of quartz-induced lipid peroxidation. J Toxicol Environ Health 1995; 46: 233-48.
41. Chen F, Lu Y, Demers LM, Rojanasakul Y, Shi X, Vallyathan V, et al. Role of hydroxyl radical in silica-induced NF-kappa B activation in macrophages. Ann Clin Lab Sci 1998; 28: 1-13.
42. Castranova V, Kang JH, Ma JK, Mo CG, Malanga CJ, Moore MD, et al. Effects of bisbenzylisoquinoline alkaloids on alveolar macrophages: Correlation between binding affinity, inhibitory potency, and antifibrotic potential. Toxicol Appl Pharmacol 1991; 108: 242-52.
43. Jin H. A experimental study on the inhibitory effect of tetrandrine on the pingyangmycinum induced pulmonary fibrosis. Chin J Tubercul Respir Dis. 1991; 14: 359-61, 378.
44. Liu HL, Lu HM, Li DG, Jiang ZM, Qi F. Effects of tetrandrine and chlorpromazine on synthesis of collagen and hyaluronic acid in cultured human lung fibroblasts. Acta Pharmacol Sin 1995; 16: 412-4.
45. Tian Z, Liu S, Li D. Blocking action of tetrandrine on the cell proliferation induced by PDGF in human lung fibroblasts and liver Ito cell of rats. Nat Med J Chin 1997; 77: 50-3.
46. Reist RH, Dey RD, Durham JP, Rojanasakul Y, Castranova V. Inhibition of proliferative activity of pulmonary fibroblasts by tetrandrine. Toxicol Appl Pharmacol 1993; 122: 70-6.
47. Li YR, Jiang HX. The reseach on silicosis therapeutic rational of tetrandrine. Chin J Indus Hygiene Occup Dis 1983; 1: 133-5.
48. Liu BC, He YX, Miao Q, Wang HH, You BR. The effects of tetrandrine and polyvinylpyridine-N-oxide (PVNO) on gene expression of type I and type III collagens during experimental silicosis. Biomed Environ Sci 1994; 7: 199-204.
49. He Y, Liu B, Miao Q. Inhibition of mRNA expression of silicotic collagen gene by tetrandrine. Chin J Prev Med 1995; 29:18-20.
50. Mo X, Chen W, Cheng D. Effect of tetrandrine on the collagen contents of lungs in rats with chronic hypoxia. Chin J Tuberculosis Respir Dis 1998; 21: 595-7.
51. Yu L, Zhou CQ, Li YR, Qu L, Xing KJ, Du QC. A biochemical study on combined treatment of experimental silicosis with tetrandrine-PVNO and tetrandrine-QOHP in rats. Biomed Environ Sci 1995; 8: 265-8.
52. Chen WB, Yan H, Mo XN. Effect of tetrandrine on expression of β-FGF in lung tissue of rat with chronic hypoxic pulmonary hypertension. J West Chin Univ Med Sci 2001; 32: 12-4.
53. Wang HL, Zhang XH, Jin X, Xing J, Zhang DR. Tetrandrine inhibited chronic "inflammatory" pulmonary hypertension in rats. Acta Pharmacol Sin 1997; 18: 401-4.
54. Zhang SF, Sun BT, Zhang J, Li FY, Lei S. Effect of tetrandrine on pulmonary hypertension induced by monocrotaline in rats. J West Chin Univ Med Sci 1995; 26: 378-80.
55. Cheng D, Chen W, Mo X. Acute effect of tetrandrine pulmonary targeting microspheres on hypoxic pulmonary hypertension in rats. Chin Med J 2002; 115: 81-3.
56. Kobayashi S, Inaba K, Kimura I, Kimura M. Inhibitory effects of tetrandrine on angiogenesis in adjuvant-induced chronic inflammation and tube formation of vascular endothelial cells. Biol Pharm Bull 1998; 21: 346-9.
57. Liu W, Feng J, Jia H, Tang Y, Hu T, Jiang X, et al. Effect of prenatal tetrandrine therapy on pulmonary vascular structural remodeling in the nitrofen-induced congenital diaphragmatic hernia rat model. Chin Med J 2000; 113: 813-6.
58. Collaborated group of silicosic treatment of tetrandrine. Clinical efficacy observation of tetrandrine on simple silicosis. Chin J Industry Hygiene Occup Dis 1983; 1: 136-9.
59. Task group of clinical evaluation on therepeutic effects of drugs treatment for silicosis. Clinical trial and evaluation of treatment for silicosis. Chin J Industry Hygiene Occup Dis 1996; 14: 130-4.
60. Li DH, Zhang CJ, Zhong YN. Clinical study on long-term therapeutic effect of combined anti-fibrosis drugs on silicosis. Chin J Indus Hygiene Occup Dis 2001; 19: 3-6.
61. Yu XX, Dang JX, Shi L, Gu PF, Xu XH, Kong FZ. Clinical observation of tetrandrine aerosol on the effect of relieving asthma. Zhejiang J Tradit Chin Med 1992; 27: 98-9.
62. Kang J, Yu RJ, Wang HL, Liu KJ. Effects of Tet on pulmonary hypertension in patients with chronic obstructive pulmonary disease. Chin J Tubercul Respir Dis 1993; 16: 93-4, 124.
63. Wang QY, Kang J, Yu RJ, Wang HL. Short-term effect of tetrandrine on pulmonary hypertension in COPD patients. J Chin Med Univ 1996; 25: 260-3.